1 Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical...
-
Upload
beverly-johns -
Category
Documents
-
view
213 -
download
0
Transcript of 1 Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical...
1
Diabetes Update
Division of Endocrinology
Department of Medicine
Wayne State University Medical School
Detroit, Michigan
Part 2 of 3
2
Why the Interest in Incretins ?
4
The Incretin Defect in Type 2 Diabetes
Insulin Resistance
Incretin“Defect”
Relative Insulin Deficiency
HyperglycemiaType 2 Diabetes
Incretin effect accounts for up to 70% of the insulin response to oral glucose intake1
1. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199-E206.
GLP-1 secreted upon the ingestion of food
7
Lifestyle + MET + PIO + SFU
Lifestyle + MET + PIO + SFU
“If hypoglycemia is particularly
undesirable…” and/or “promotion of
weight loss is a consideration…”
“If hypoglycemia is particularly
undesirable…” and/or “promotion of
weight loss is a consideration…”
ADA/EASD Consensus Statement Includes a GLP-1 Receptor Agonist
STEP 1 At diagnosis: Lifestyle + MET
STEP 2 Tier 1: Well-validated core therapies*
STEP 3 Lifestyle + MET + intensive insulin
OR
If A1C ≥7%If A1C ≥7%
MET, metformin PIO, pioglitazone SFU, sulfonylurea
*Validation based on clinical trials and clinical judgment.†Insufficient clinical use to be confident regarding safety. Adapted from Nathan DM, et al. Diabetes Care. 2009.
Lifestyle + MET + basal insulin
Lifestyle + MET + basal insulin
Lifestyle + MET + SFU
Lifestyle + MET + SFU
Lifestyle + MET + basal insulin
Lifestyle + MET + basal insulin
Tier 2: Less well-validated therapies*
Lifestyle + MET + PIO
Lifestyle + MET + PIO
Lifestyle + MET +GLP-1 receptor
agonist†
Lifestyle + MET +GLP-1 receptor
agonist†
EXUBERAEXUBERA®®
(insulin human [rDNA origin])(insulin human [rDNA origin])Inhalation PowderInhalation Powder
Liraglutide (Victoza)Liraglutide (Victoza)and Exenatide (Byetta)and Exenatide (Byetta)
Newer GLP 1 analogue.Newer GLP 1 analogue.
Indicated in monotherapy or in combination with Indicated in monotherapy or in combination with metformin, SU, TZD, or combination therapy.metformin, SU, TZD, or combination therapy.
Dosed once or twice daily Dosed once or twice daily
Uses the convenient pen.Uses the convenient pen.
Maintains weight loss and glycemic control.Maintains weight loss and glycemic control.
99
Why Insulin in Type 2 DiabetesWhy Insulin in Type 2 Diabetes??
1212
Mimicking Physiology: Mimicking Physiology: Basal and Prandial InsulinBasal and Prandial Insulin
Breakfast Lunch Dinner
4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00
Pla
sma
Insu
lin
Time
Basal1/day
Prandial Insulin 3/day
Plus